BACKGROUND: Systemic inflammation in bronchiectasis is poorly studied in relation to aetiology and severity. We hypothesized that molecular patterns of inflammation may define particular aetiology and severity groups in bronchiectasis.
Introduction
Bronchiectasis is a neglected chronic inflammatory airway condition that is the end anatomical result of diverse aetiological insults. Whilst it has been known for some time that bronchiectasis is also associated with systemic inflammation [1] , the nature of this response has not been well studied in relation to bronchiectasis aetiology and severity.
Importantly, no previous studies have examined whether inflammation differs between major causes of bronchiectasis such as idiopathic and post-infectious disease. Indeed, there are no existing data examining a comprehensive panel of inflammatory proteins in the systemic compartment of patients with bronchiectasis.
Current concepts of bronchiectasis severity emphasise the importance of multi-component assessment [2, 3] . Scores such as the Bronchiectasis Severity Index (BSI) [2] and FACED [3] predict mortality, hospital admissions, exacerbation frequency and quality of life. There is also a paucity of data examining causes of death in bronchiectasis despite a suggestion of increased cardiovascular risk [4] . This is a concept well established in other chronic airway diseases such as chronic obstructive pulmonary disease (COPD) and which may relate to systemic inflammation [5] . There is therefore the need to examine how bronchiectasis severity is associated with systemic inflammation and, in particular, which components of bronchiectasis severity drive this association.
We designed a study to address the hypotheses that systemic inflammatory markers can distinguish aetiology and severity groups in bronchiectasis, employing an unsupervised principal component analysis. In doing so we have conducted the largest and most comprehensive analysis of systemic inflammatory proteins in bronchiectasis ever reported.
Moreover, we validated key results in two replication cohorts. Our results inform on the heterogeneity of systemic inflammatory responses in bronchiectasis with regard to aetiology and severity of disease.
Method 90 patients with stable, clinically significant bronchiectasis -regular sputum production and/or recurrent respiratory infections with a diagnostic computed tomography (CT) scanwere recruited as a convenience sample from out-patient clinics at the Royal Free London and University College London Hospitals NHS Foundation Trusts, UK. Patients with a primary clinical diagnosis of COPD were excluded. These patients formed the derivation cohort.
Patients were only recruited if free from exacerbation for one month or more. Patients provided written informed consent, and the study was approved by Hampstead Research Ethics Committee (10/H0720/43).
Clinical Assessment
For the purposes of this analysis, information was collated to permit allocation of patients into aetiological groups according to the British Thoracic Society guideline [6] . Idiopathic disease was defined as the absence of an alternative more plausible cause of bronchiectasis.
Bronchiectasis severity was first assessed using the Bronchiectasis Severity Index [2] and therefore data on age, body mass index (BMI), most recent lung function (forced expiratory volume in 1 second, FEV1), self-reported hospitalisation (previous two years) and exacerbations (previous year), Medical Research Council (MRC) dyspnoea scale, the presence of colonising organisms on routine sputum culture and radiological extent of disease on the most recent CT scan were collated and entered into the online BSI calculation tool: http://www.bronchiectasisseverity.com/. Mild bronchiectasis was defined as a score of 0-4, moderate as 5-8 and severe as ≥9 units. To provide further information in relation to bronchiectasis severity, we also calculated the alternative FACED bronchiectasis severity score [3] , which includes age, FEV1, lobar involvement, dyspnoea (mMRC score) and
Pseudomonas colonisation status. The FACED score is as follows: mild 0-2 points, moderate 3-4 points and severe 5-7 points.
Assessment of Serum Proteins
Venous blood samples were drawn. A citrated plasma sample was analysed for fibrinogen using the Clauss method (IL ACL Top Coagulation Analyzer; Instrumentation Laboratories, Lexington, MA). A serum sample was analysed for C-Reactive Protein using a Modular Analytics E 170 Module (Roche, Burgess Hill, UK). A second serum sample was centrifuged (10 minutes, 2000rpm, 4 O C) with the supernatant then stored at -80 O C for later analysis of the remaining 29 mediators (see Table 1 ). These were assessed using the Meso Scale Discovery Platform 'V-PLEX Human Cytokine 30-Plex Kit' (Meso Scale Discovery, Rockville, MD, US) according to the manufacturer's instructions.
Validation Cohorts
Key results were validated in two samples of patients from specialist bronchiectasis clinics in Dundee and Newcastle, UK. These patients had clinically significant bronchiectasis and also underwent standardised testing according to BTS recommendations, as in the derivation cohort. Ethical approval was granted (12/ES/0059 and 12/NE/0248 respectively). 
Statistical Analysis
Statistical analysis was performed in IBM SPSS version 22 (IBM Corporation, Armonk, NY, US). Data were tested for normality using the Kolmogorov-Smirnov test. Clinical data are reported as mean and standard deviation (SD) or median and interquartile range (IQR) as appropriate.
The majority of the serum proteins were not normally distributed and therefore all were log10 transformed for further analysis. As described in Table 1 , any assays below the detection limit were assigned a value of half that lower limit of detection (LLD). 17 missing fibrinogen results in the derivation cohort arising because no plasma sample was available were single-imputed based on a significant correlation between fibrinogen and CRP (rho=0.572, p<0.001). We validated a key finding in relation to fibrinogen using minimum, mean and maximum values derived from multiple imputation using the 'mi' command in STATA version 14 (www.stata.com).
We used Principal Component Analysis (PCA) [7] to assess variation in the proteins across the population. The protein most closely correlated with each of the first five principal components was selected as a key exemplar protein for that principal component. 6 Radar plots [8] were employed to illustrate the concentrations of these five key proteins across disease severity and aetiology. To do this, the concentration of each of these proteins was expressed as the quartile of the concentration it was contained in, derived from the concentrations across all 90 patients. The mean of each of these quartile values was then used to construct the radar plot.
Correlations were assessed using Pearson or Spearman Rank as appropriate, and differences between medians tested by Mann-Whitney U analysis for two groups, and Kruskal-Wallis one-way analysis of variance when more than two groups were tested. We also employed multiple linear regression and receiver-operating characteristic (ROC) analysis.
A p value <0.05 was considered statistically significant.
Results
The 90 patients (57, 63% women) in the derivation cohort had a median (IQR) age of 61 (46-71) years, BSI score of 5 (3) (4) (5) (6) (7) (8) Table 1 . 109.6 (1.9) Values below the lower limit of detection were assigned a value of half that lower limit.
Principal Component Analysis
Great heterogeneity was observed in the analysis of systemic protein markers across the dataset. An unsupervised principal component analysis met the criteria for data adequacy (Bartlett's test of Sphericity and Kaiser-Meyer-Olkin measure of sample adequacy) and yielded 10 factors with an Eigen value>1. Monte-Carlo parallel analysis based on a theoretical population of 100 subjects suggested a five factor solution, which then explained only 52% of the variance. Table 2 presents We next went on to explore differences by disease severity (BSI and FACED score) and aetiology in patterns of these components, using the first key cytokine associated with that component. In both the total derivation cohort and the selected patients with post-infectious aetiology, there was a step-wise increase in fibrinogen from mild through moderate to severe patients, but significant heterogeneity in the other four markers. Reflecting this, in the whole derivation cohort, we observed a significant correlation between the plasma fibrinogen concentration and BSI score (rho=0.34, p=0.001, Figure 2A ). This was robust to analysis using minimum, mean and maximum fibrinogen values derived from multiple rather than single (CRP-based) imputation (r=0.23 p=0.03; r=0.37 p<0.001 and r=0.41 p<0.001 respectively). A similar relationship was present between bronchiectasis severity assessed by the FACED score and plasma fibrinogen concentration (rho=0.27, p=0.014, Figure 2B ).
Bronchiectasis Severity and Systemic Inflammatory Proteins
There were no significant correlations between BSI score and the other four markers.
We sought to validate the relationship between BSI and plasma fibrinogen by replicating this finding in a separate cohort. Fibrinogen concentration was available in 97 patients from Dundee, UK. These patients had a median (IQR) age 65 (58-72) years and FEV1 1.72 (1.11-2.48)l, 50% were female and the two commonest aetiologies were idiopathic (46%) and post-infectious (19%) disease. Only three patients in this cohort had primary immunodeficiency. The median (IQR) BSI was 7 (4-12) and fibrinogen 3.6 (2.7-4.8) g/l.
There was a significant relationship between BSI and fibrinogen in this second independent group of patients (rho= 0.36, p<0.001), of strikingly similar strength to that in the derivation cohort thus demonstrating the finding to be robust. There was also a significant relationship between plasma fibrinogen and the St. George's Respiratory Questionnaire (rho=0.25, p=0.013), indicating that fibrinogen also reflects health-status in bronchiectasis.
Finally, we examined which components of the BSI score were most closely associated with the plasma fibrinogen concentration by conducting a multi-variable analysis with fibrinogen as the dependent variable and each of the BSI components included as predictors (using the allocated BSI 'points' rather than raw values [2] ). This was conducted in the combined UCL Next, we went on to test the principle that IL-17, as an exemplar serum protein, might be of practical use in the diagnosis of bronchiectasis aetiology. Figure 4 
Bronchiectasis Aetiology and Systemic Inflammatory Proteins

presents a Receiver
Operating Characteristic (ROC) curve for the ability of IL-17 to distinguish primary immunodeficiency from idiopathic and post-infectious aetiology. The area under the curve ((AUC)=0.769 (95%CI 0.661-0.877, p<0.001)) approaches the standard 0.8 cut off for utility, which falls within the 95%CI. Reporting geometric means, a serum IL-17 concentration of 3.23pg/ml would be 90% sensitive and 63% specific, and a concentration of 6.46pg/ml would be 90% specific and 50% sensitive for the identification of bronchiectasis associated with primary immunodeficiency. We have not reported positive and negative predictive values as these are dependent on prevalence.
We next sought to validate the difference in serum IL-17 between primary immunodeficiency versus idiopathic and post-infectious disease by replicating this finding in Finally, as were specifically interested in differences in protein expression in patients with idiopathic versus post-infectious disease, we compared the median values of the remaining 26 markers across these two groups in the derivation cohort. The only significant difference was for IL-4, which was higher in the post-infectious than the idiopathic group (p=0.025), but IL-4 was detectable in only 37 of 90 patients ( 
Discussion
We present the most comprehensive analysis of systemic immune and inflammatory proteins from patients with bronchiectasis ever reported. Our findings may be summarised thus: first, there is significant heterogeneity in systemic proteins between patients which is not fully accounted for by differences in either bronchiectasis aetiology, or bronchiectasis severity. Second, a global assessment of bronchiectasis severity (and health status) is associated with an increasing systemic acute-phase response. Third, we demonstrate the important principle that profiles of serum inflammatory proteins may differ significantly between aetiology subgroups, but we were unable to demonstrate significant differences in patterns of proteins between idiopathic and post-infectious disease.
The classic vicious cycle hypothesis of Cole [9] presents (airway) inflammation as a key component of bronchiectasis. It has been known for some time that patients with bronchiectasis also present a systemic inflammatory response [1] including up-regulated expression of circulating leukocyte adhesion molecules [10] even when clinically stable. The former analysis of differential leukocyte count, CRP, erythrocyte sedimentation rate and serum immunoglobulins in 87 patients reported significant associations between systemic inflammation and bronchiectasis severity as assessed both by CT scan and lung function. It was subsequently shown that systemic inflammation is elevated in patients with high airway bacterial load, and that this effect can be modified with antibiotic therapy [11] . We now recognise bronchiectasis as a complex disease which is best assessed using multicomponent scores [2, 3] . MCP-1 (CCL2) is a CC chemokine responsible for recruiting monocytes, T-lymphocytes and dendritic cells to sites of inflammation [12] . A role for MCP-1 has not previously been reported in bronchiectasis. Further work is required to explore the factors determining the variance in this marker between patients, and its potential as an outcome marker or therapeutic target. Whilst bronchiectasis is usually considered a condition of principally neutrophilic inflammation, variance in serum IL-8 concentration was also unexplained by differences in bronchiectasis aetiology and severity. This is perhaps not surprising as recruitment and activation of neutrophils occurs locally in the airway and not in the systemic circulation.
With the possible exception of IL-4, we were unable to define differences in systemic protein responses between individuals with idiopathic and post-infectious bronchiectasis, the two commonest causes in clinical practice in the developed world. Further study of IL-4 in this context is warranted. However, differentiating between idiopathic and postinfectious bronchiectasis is challenging because patients classified as idiopathic may have had unreported respiratory infection, and where bronchiectasis is classified as postinfectious there may be recall bias with tenuous linkage to a previous, often childhood, infection. Anwar et al [13] suggested that post-infectious bronchiectasis may be a valid subgroup as patients had an earlier onset of disease, but evidence to date as to whether idiopathic and post-infectious disease are separate phenotypes remains inconclusive. Our data demonstrate that these aetiologies are difficult to differentiate in terms of systemic inflammatory profiles.
Our finding of greater IL-17 responses in patients with primary immunodeficiency was validated in an independent cohort. This raises the possibility that assessment of serum proteins may have utility in the differential diagnosis of bronchiectasis although prospective analysis would be required to confirm such a hypothesis. IL-17 has a key role in inducing and mediating pro-inflammatory responses [14] . [17] [18] [19] ) have been shown to reduce IL-17 expression in patients with bronchiectasis [20] .
Global assessments of bronchiectasis severity (BSI and FACED score) were associated with an increasing acute-phase response, exemplified by plasma fibrinogen concentration, and we replicated this result in an independent cohort. This effect was driven largely by the reduction in lung function, Pseudomonas colonisation and age. Our findings are in keeping with Wilson's 1998 report of an association between lung function and systemic inflammation in bronchiectasis [1] . Systemic inflammation may provide the link between airway inflammatory diseases and the increased cardiovascular risk observed in such conditions [5] , of clinical importance because many patients with COPD, for example, die from co-morbid cardiovascular disease [21] . As a coagulation protein, fibrinogen may be directly involved in cardiovascular risk. The concept of cardiovascular risk in bronchiectasis is poorly studied, but we have recently reported that patients with bronchiectasis are at increased risk of cardiovascular events compared to a control population [4] . Our results raise the hypothesis that preservation of lung function and, perhaps, prevention of Pseudomonas colonisation could be important strategies to mitigate the excess cardiovascular risk associated with bronchiectasis. The utility of biomarkers such as fibrinogen in adding to mortality prediction in COPD [22] has resulted in FDA consideration of this protein as a surrogate outcome measure in clinical trials in COPD [23] . There is therefore the need to understand further the role of fibrinogen in bronchiectasis.
A major strength of our study is that we have validated our two key findings in independent cohorts. However a limitation, common to all bronchiectasis studies, is that populations vary across centres depending on local referral patterns. In our derivation population, for example, we were not able to explore systemic protein responses in bronchiectasis associated with other immune-dysregulated conditions such as rheumatoid arthritis. Whilst We were not able to study relationships between airway bacterial density or the microbiome and systemic proteins, a limitation of our work and this would be an important area for future research. All samples were taken from patients at least one month following a preceding exacerbation; it is possible that in some patients inflammatory responses may not have fully resolved. Furthermore, the range of anti-inflammatory and anti-infective medications used in our cohort prevent us from commenting on the effect of individual or combination therapies on systemic protein concentrations, which would therefore also be a further important area of future study.
In summary, we report significant heterogeneity in systemic inflammation between patients with bronchiectasis. This heterogeneity is not solely associated with either disease aetiology or severity. Indeed, the profiles of inflammation were generally similar in heterogeneity across the two most important aetiologies: idiopathic and post-infectious disease. A global index of bronchiectasis severity was associated with an increased acute-phase response, in two cohorts. This finding offers insight into a possible role for fibrinogen and increased cardiovascular risk in bronchiectasis. We also provide proof-of-principle that assessment of systemic proteins may support diagnosis of rarer, specific causes of bronchiectasis.
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2B: 25 FIGURE 3: Radar plots of five serum inflammatory proteins by the three most common aetiologies of bronchiectasis in the whole derivation cohort ( Figure 3A) and only those patients with moderate disease ( Figure 3B ). The blue line represents idiopathic patients, the purple line post-infectious patients and the black line patients with primary immunodeficiency. Numbers refer to quartiles of (log10) serum concentration. 
